Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.

Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB

JPEN. Journal of parenteral and enteral nutrition21 Apr 2019Cited by 48 (Europe PMC)

PMID31006876PMCIDPMC7004164DOI10.1002/jpen.1588PepBankPUB-31006876

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with SBS, teduglutide changed the SBS-QoL sum score by -8.6 points (a nonsignificant improvement; 95% CI 2.6 to -19.8) from baseline to Week 24 versus placebo.
In plain wordsIn adults with SBS, teduglutide numerically improved quality-of-life scores versus placebo, without statistical significance.
Peptide
Teduglutide
Outcome
DecreaseSBS-QoL sum score at Week 24
Study
n = 86
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated
Measurements
Adjusted difference in SBS-QoL sum score change vs placebo
−8.6 points
overall population, Week 24
95% CI of adjusted difference
−19.8 to 2.6 points
overall population, Week 24
Source sentences
Summary
In adjusted analyses, teduglutide had a nonsignificant reduction (improvement) of -8.6 points (95% CI: 2.6 to -19.8) in SBS-QoL sum score from baseline to Week-24 vs placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Using phase 3 trial data of teduglutide in patients with SBS (NCT00798967), change in Short Bowel Syndrome-Quality of Life (SBS-QoL) scores from baseline were compared between teduglutide vs placebo in the overall population and subgroups classified by baseline PS volume requirement, disease etiolog…
Summary · context
Of 86 patients, 43 each were randomized to teduglutide or placebo (mean age: 51 vs 50 years, respectively).
Report a problemFND-3100687601
02HumanRandomized controlled trialEfficacy outcome
In adults with SBS in the highest baseline PS volume tertile, teduglutide produced a significantly greater reduction in SBS-QoL sum score at Week 24 versus placebo (-27.3, 95% CI -50.8 to -3.7).
In plain wordsIn adults with SBS and highest baseline support needs, teduglutide improved quality-of-life scores more than placebo.
Peptide
Teduglutide
Outcome
DecreaseSBS-QoL in highest baseline PS tertile
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated
Measurements
Difference in SBS-QoL sum score change vs placebo
−27.3 points
highest baseline PS volume tertile, Week 24
95% CI of difference
−50.8 to −3.7 points
highest baseline PS volume tertile, Week 24
Source sentences
Summary
Patients treated with teduglutide experienced significantly greater reductions in SBS-QoL sum score at Week-24 vs placebo in 2 subgroups, ie, the third (highest) tertile baseline PS volume (-27.3, 95% CI: -50.8 to -3.7) and inflammatory bowel disease (IBD; -29.6, 95% CI: -46.3 to -12.9).
2 context sentences(design, population, supporting numbers)
Summary · context
Using phase 3 trial data of teduglutide in patients with SBS (NCT00798967), change in Short Bowel Syndrome-Quality of Life (SBS-QoL) scores from baseline were compared between teduglutide vs placebo in the overall population and subgroups classified by baseline PS volume requirement, disease etiolog…
Summary · context
Of 86 patients, 43 each were randomized to teduglutide or placebo (mean age: 51 vs 50 years, respectively).
Report a problemFND-3100687602
03HumanRandomized controlled trialEfficacy outcome
In adults with SBS and IBD, teduglutide produced a significantly greater reduction in SBS-QoL sum score at Week 24 versus placebo (-29.6, 95% CI -46.3 to -12.9).
In plain wordsIn adults with SBS and IBD, teduglutide improved quality-of-life scores more than placebo.
Peptide
Teduglutide
Outcome
DecreaseSBS-QoL in IBD subgroup
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated
Measurements
Difference in SBS-QoL sum score change vs placebo
−29.6 points
IBD subgroup, Week 24
95% CI of difference
−46.3 to −12.9 points
IBD subgroup, Week 24
Source sentences
Summary
Patients treated with teduglutide experienced significantly greater reductions in SBS-QoL sum score at Week-24 vs placebo in 2 subgroups, ie, the third (highest) tertile baseline PS volume (-27.3, 95% CI: -50.8 to -3.7) and inflammatory bowel disease (IBD; -29.6, 95% CI: -46.3 to -12.9).
2 context sentences(design, population, supporting numbers)
Summary · context
Using phase 3 trial data of teduglutide in patients with SBS (NCT00798967), change in Short Bowel Syndrome-Quality of Life (SBS-QoL) scores from baseline were compared between teduglutide vs placebo in the overall population and subgroups classified by baseline PS volume requirement, disease etiolog…
Summary · context
Of 86 patients, 43 each were randomized to teduglutide or placebo (mean age: 51 vs 50 years, respectively).
Report a problemFND-3100687603
04HumanRandomized controlled trialEfficacy outcome
In adults with SBS, teduglutide effects versus placebo on SBS-QoL subscale and item scores were similar to sum-score results.
In plain wordsIn adults with SBS, teduglutide versus placebo showed similar patterns across quality-of-life subscales, items and total scores.
Peptide
Teduglutide
Outcome
Direction not reportedSBS-QoL subscale and item scores
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Results were similar for SBS-QoL subscale and item scores.
4 context sentences(design, population, supporting numbers)
Summary · context
In adjusted analyses, teduglutide had a nonsignificant reduction (improvement) of -8.6 points (95% CI: 2.6 to -19.8) in SBS-QoL sum score from baseline to Week-24 vs placebo.
Summary · context
Patients treated with teduglutide experienced significantly greater reductions in SBS-QoL sum score at Week-24 vs placebo in 2 subgroups, ie, the third (highest) tertile baseline PS volume (-27.3, 95% CI: -50.8 to -3.7) and inflammatory bowel disease (IBD; -29.6, 95% CI: -46.3 to -12.9).
Summary · context
Using phase 3 trial data of teduglutide in patients with SBS (NCT00798967), change in Short Bowel Syndrome-Quality of Life (SBS-QoL) scores from baseline were compared between teduglutide vs placebo in the overall population and subgroups classified by baseline PS volume requirement, disease etiolog…
Summary · context
Of 86 patients, 43 each were randomized to teduglutide or placebo (mean age: 51 vs 50 years, respectively).
Report a problemFND-3100687604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase not statedNCT04733066

Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis

Charite University, Berlin, Germanyn = 401 Sept 2020 to est. Sept 2022

Short Bowel Syndrome · Intestinal Failure

Trial page ClinicalTrials.govUpdated 1 Feb 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.